Liver chemistries in severe or non-severe cases of COVID-19: A systematic review and meta-analysis.
World J Hepatol
; 14(12): 2012-2024, 2022 Dec 27.
Article
in English
| MEDLINE | ID: covidwho-2202198
ABSTRACT
BACKGROUND:
Coronavirus disease (COVID-19) patients exhibit different patterns of liver impairment, according to growing evidence.AIM:
In this study, we sought to provide a comprehensive analysis of liver test parameters in patients with severe and non-severe COVID-19.METHODS:
We performed a meta-analysis of published liver manifestations and described the liver damage in COVID-19. We searched PubMed, Google Scholar, Embase, Cochrane Library, medRxiv, bioRxiv, and three Chinese electronic databases through April 18, 2020, in accordance with the Preferred Reporting Items for Meta-Analyses. We analyzed pooled data on liver chemistries stratified by COVID-19 severity using a fixed or random-effects model.RESULTS:
A meta-analysis of 56 studies, including 11052 patients, found that the pooled mean alanine aminotransferase (ALT) in severe COVID-19 cases was 35.9 IU/L whereas in non-severe COVID-19 cases was 27.3 IU/L. Average aspartate aminotransferase (AST) levels were 44.3 IU/L in severe cases compared to 27.9 IU/L in non-severe cases. In addition, AST levels are often higher than ALT levels regardless of disease severity. The severe cases tended to have a higher gamma-glutamyltransferase level but a lower albumin level than the non-severe cases.CONCLUSION:
Severe COVID-19 was more likely to be associated with abnormal liver test results. Monitoring liver chemistry closely can help detect disease progression early.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Prognostic study
/
Randomized controlled trials
/
Reviews
/
Systematic review/Meta Analysis
Language:
English
Journal:
World J Hepatol
Year:
2022
Document Type:
Article
Affiliation country:
Wjh.v14.i12.2012
Similar
MEDLINE
...
LILACS
LIS